BioCryst Pharmaceuticals does not have a long track record of dividend growth. 52 Week High $13.92. BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX.". According to 10 analysts, the average rating for BCRX stock is "Buy." The stock broke below $10 for the first time on March 18 and ultimately bottomed at $7.80 in early April. View which stocks are hot on social media with MarketBeat's trending stocks report. Analysts tracking BCRX have forecast the quarterly EPS to grow by -$0.28 per share this quarter, while the same analysts predict the annual EPS to hit -$1.05 for the year 2021 and up to -$0.73 for 2022. Facebook. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; Consensus Rating: Buy; Consensus Price Target: $9.07; Forecasted Upside: 48.71 %; Number of Analysts: 10; Breakdown: 0 Sell Ratings; 3 Hold Ratings; 7 Buy Ratings; 0 Strong Buy Ratings $ 6.10 As of 12/4/2020 01:00 AM ET +0.96 (18.68%) … High institutional ownership can be a signal of strong market trust in this company. Watchlist. BioCryst Pharmaceuticals closed on Monday at $11.10 after barely changing a -0.45%. Create Close. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Top institutional investors include BlackRock Inc. (9.21%), Northern Trust Corp (1.17%), Nuveen Asset Management LLC (0.94%), Renaissance Technologies LLC (0.73%), Charles Schwab Investment Management Inc. (0.66%) and Voloridge Investment Management LLC (0.59%). BCRX Stock Trend. View analysts' price targets for BioCryst Pharmaceuticals or view top-rated stocks among Wall Street analysts. BCRX Stock Forecast - Get a free BCRX stock predictions and find out whether you should buy or sell BCRX stock. Post-Market 0.09 (0.69%) BioCryst stock forecast & analyst price target predictions based on 10 analysts offering 12-months price targets for BCRX in the last 3 months. Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock … Should I buy or sell BCRX stock? Biocryst Pharmaceuticals Stock Forecast, BCRX stock price prediction. Vote “Outperform” if you believe BCRX will outperform the S&P 500 over the long term. Analyst / Firm Rating Action Price Target Upside/Downside Date; Gena Wang. View real-time stock prices and stock quotes for a full financial overview. The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. Learn everything you need to know about successful options trading with this three-part video course. BCRX Stock Predictions. Miguel Garrison - January 11, 2021. BCRX Stock Predictions. Shares of BCRX can be purchased through any online brokerage account. The extremes of the forecast give a target low and a target high price of $9 and $16 respectively. The average price target is $9.86, with a high forecast of $14.00 and a low forecast of $6.00. All All Strong Buy Buy Hold Sell Strong Sell. Bullish. BCRX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Voloridge Investment Management LLC, Norges Bank, BlackRock Inc., North Star Investment Management Corp., Silverarc Capital Management LLC, Price T Rowe Associates Inc. MD, and Los Angeles Capital Management LLC. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%.During that period the price should oscillate between … BCRX Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Learn more. BioCryst Pharmaceuticals has a market capitalization of $2.35 billion and generates $48.83 million in revenue each year. 8 of the analysts rate the stock as a “Buy”. High Growth Revenue: BCRX's revenue (42.4% per year) is forecast to grow faster than 20% per year. Over the past year the S&P 500 is higher by 15.01% while BCRX is higher by 179.05%. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. BCRX Sentiment 100% Sector Average 70%. View insider buying and selling activity for BioCryst Pharmaceuticals or or view top insider-buying stocks. During that period the price should oscillate between … Market Cap $2.23B. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy." The BioCryst Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Long. The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. At that level, BCRX’s share price would be +2.19% above current price. BioCryst Pharmaceuticals Stock Forecast NASDAQ:BCRX. Their average twelve-month price target is $11.78, predicting that the stock has a possible downside of 11.04%. Find the latest BioCryst Pharmaceuticals, Inc. (BCRX) stock quote, history, news and other vital information to help you with your stock trading and investing. BCRX Blogger Predictions > Hedge Fund Activity . Fair Value Price. BCRX stock forecast Our latest prediction for Biocryst Pharmaceuticals Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.. 1W +13.36% 1M +32.08% 3M +48.71% 1Y +525.74% All. No recent news for BioCryst Pharmaceuticals Inc. (Add your “underperform” vote.). By. BCRX stock forecast for the next 10 days by pretiming. 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. BCRX Stock Forecast. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. BCRX | Complete BioCryst Pharmaceuticals Inc. stock news by MarketWatch. BioCryst Pharmaceuticals made public its earnings report on February 25 ; BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. P/S 69.96x. BioCryst Pharmaceuticals, Inc. NASDAQ Updated Mar 16, 2021 11:59 PM BCRX 13.01 0.47 (3.49%). Stock Coverage; Markets; BioCryst Pharmaceuticals Inc. (BCRX) Review – Making Smarter Decisions. Should I buy or sell BCRX? To see how BioCryst Pharmaceuticals, Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: BCRX stock’s performance was -3.26% at last check in today’s session, and +133.84% in the past year, while Zoetis Inc Cl A (ZTS) has been trading +0.87% in recent session and positioned +24.47% higher than it was a year ago. Fundamental company data provided by Zacks Investment Research. This price target is based on 10 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. Bullish. Trend. BCRX, 1D. BioCryst Pharmaceuticals' management team includes the following people: President, Chief Executive Officer & Director, Chief Financial Officer & Senior Vice President, Chief Medical Officer & Senior Vice President, Secretary, Chief Legal Officer & Senior VP, Chief Business Officer & Senior Vice President, Start Your Risk-Free Trial Subscription Here, 3 Homebuilder Stocks Making Constructive Moves, Whatever You Believe About Sundial Growers, You Could Be Right, SunPower Stock is a Best of Breed Solar Play, The Exodus Movement, Inc Ushers In A New Age Of IPO, Ford Stock Gains Big on Upgrade at Barclays, Nike Slips On Earnings, Traction Forecast For Later In The Year, FedEx Breaks Out On Q3 Earnings And Outlook, Cintas Falls On Great Results, Growth Is Back On The Table, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, First Week of May 21st Options Trading For BioCryst Pharmaceuticals (BCRX), BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer, BioCryst to Host Virtual R&D Day on March 22, 2021, Biocryst’s berotralstat granted early access for HAE in France, Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France, BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema, Why BioCryst Pharmaceuticals Stock Is Popping Today, BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema, BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema, BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript, Why BioCryst Pharmaceuticals Stock Is Falling Today, BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates, BioCryst Pharmaceuticals, Inc. to Host Earnings Call, BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones. You can opt out at any time. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Thinking about buying or selling stock in BCRX? Revenue vs Market: BCRX's revenue (42.4% per year) is forecast to grow faster than the US market (10.1% per year). ), BioCryst Pharmaceuticals has received 408 “underperform” votes. Strong Buy. Get the latest Detailed Estimate from Zacks Investment Research. BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. View live BIOCRYST PHARMACEUTICALS INC chart to track its stock's price action. See what's happening in the market right now with MarketBeat's real-time news feed. BioCryst Pharmaceuticals had a negative trailing twelve-month return on equity of 328.70% and a negative net margin of 233.45%. WhatsApp. Detailed Estimate. BCRX Stock Forecast - Is BCRX a buy or sell? Trading Signals: BCRX Stock Price Prediction and Forecast (Tue. One share of BCRX stock can currently be purchased for approximately $13.24. What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares? Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. BCRX. BCRX stock forecasts by analyst. Disclaimer. 2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Buy”. BCRX forecasts Videos only. If you are thinking about buying BCRX, make sure you check out the free BCRX stock predictions report provided by MarketClub. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. 12, 2021. See the latest Biocryst Pharma Inc (BCRX) stock analysis, price, forecast, news and more. Want to see which stocks are moving? P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. There are currently 3 hold ratings and 8 buy ratings for the stock. Should I buy or sell BCRX stock? Get daily stock ideas top-performing Wall Street analysts. ... BCRX Stock Predictions, Articles, and Biocryst Pharma Inc News. 52 Week Low $1.58. In this case, analysts estimate an annual EPS growth of -0.04% for the year and -0.3% for the next year. Notifications > RSS.feed pretiming (Go to RSS.feed) > Pretiming analysis will be updated one by one at GMT 0:00 everyday > Please read a guide how to use pretiming analysis. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. BCRX -- USA Stock : USD 10.90 0.02 0.18% : Biocryst Pharma Stock Forecast is based on your current time horizon. Stop-loss: $12.32 (-5.29%) Price … BCRX Sentiment 100% Sector Average 70%. Pinterest. Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Buy”. View which stocks have been most impacted by COVID-19. BioCryst Pharmaceuticals has received a consensus rating of Buy. Wall Street analysts have given BioCryst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. View BioCryst Pharmaceuticals' earnings history. BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts. The biotechnology company can be reached via phone at (919) 859-1302 or via email at [email protected]. Top authors: BCRX. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Three analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. 3M 12M Bollinger Which way will BCRX go? Price Target The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.09. The trend analysis tool will help you make a better prediction on the BCRX stock. Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Post-Market 0.09 (0.69%) © 2020 Cable News Network. Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years. Receive a free world-class investing education from MarketBeat. BCRX Related ETF s. Symbol %Holdings 3M %Chg; BCRX +55.67% : Biocryst Pharma Inc: XBI : 1.36% +2.98% : S&P Biotech SPDR: IWM : 0.08% +22.75% : Russell 2000 Ishares ETF: IBB : 0.19% +3.04% : Nasdaq Biotechnology Ishares ETF: IWO : 0.13% +15.30% : Russell 2000 Growth Ishares ETF: VTI : 0% +9.05% : Total Stock Market ETF Vanguard: Symbol %Holdings 3M %Chg; BCRX … Investors can use this forecasting interface to forecast Biocryst Pharma historical stock prices and determine the direction of Biocryst Pharma's future trends based on various well-known forecasting models. BioCryst Pharmaceuticals, Inc. (BCRX) stock price forecast. Apr. MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. BioCryst Pharmaceuticals employs 140 workers across the globe. BCRX Stock Analysis Overview What this means: Biocryst Pharma Inc (BCRX) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. The consensus price target of analysts on Wall Street is $13.9, which implies an increase of 3.42% to the stock’s current value. Get short term trading ideas from the MarketBeat Idea Engine. 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. P/B -115.86x. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Trend. sentiment. The high price target for BCRX is $16.00 and the low price target for BCRX is $6.00. To see all exchange delays and terms of use please see disclaimer. In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%. The consensus price target of analysts on Wall Street is $13.9, which implies an increase of 3.42% to the stock’s current value. Increased. Factset: FactSet Research Systems Inc.2019. BioCryst Pharmaceuticals has received 437 “outperform” votes. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Their forecasts range from $6.00 to $16.00. BCRX stock brief. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. The current price is about -34.31% off the estimated low and 16.79% off the forecast high, based on this estimate. Find the latest Earnings Report Date for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. The 12-month stock price forecast is 13.78, which is an increase of 5.92% from the latest price. BioCryst climbs after FDA approval for Rapivab in infants, BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older, BioCryst Pharmaceuticals Reaches Analyst Target Price, The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. BCRX stock price history chart Price target for BioCryst Pharmaceuticals stock. Looking for new stock ideas? 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Long since 1.90's. 11 brokers have issued 12-month price targets for BioCryst Pharmaceuticals' shares. N/A. BCRX Only Stock to Own. Vote “Underperform” if you believe BCRX will underperform the S&P 500 over the long term. 209 institutions hold shares in BioCryst Pharmaceuticals Inc. (BCRX), with 1.51M shares held by insiders accounting for 0.85% while institutional investors hold 74.58% of the company’s shares. View our full suite of financial calendars and market data tables, all for free. Bullishcharts Last visit Follow Following Unfollow. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, and Steve Aselage. Access to Intraday penny stock screener Scan for strong stocks Never miss a profitable trade. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. 3M +48.71% 1W +13.36% 1M +32.08% 3M +48.71% 1Y +525.74% All. View our earnings forecast for BioCryst Pharmaceuticals. Dividend … P/E -11.6x. BioCryst Pharmaceuticals, Inc. (BCRX) projections and forecasts. Should I buy BioCryst Pharmaceuticals stock? In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock. 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. Learn more. 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. Request. BCRX Price $12.64. BCRX is higher by $0.61 from the previous closing price of $7.65 on volume of 5,929,634 shares. BCRX stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, UBS Asset Management Americas Inc., Credit Suisse AG, Victory Capital Management Inc., Barclays PLC, Pura Vida Investments LLC, SG Americas Securities LLC, and Edge Wealth Management LLC. Increased. 8 of the analysts rate the stock as a “Buy”. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. If I had to chose one stock to own this next year you are looking at it. Average Price Target : $13.00. NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions. Biocryst Pharmaceuticals Inc. Stock Price Forecast, "BCRX" Predictons for2021 The stock lies in the middle of a wide and strong rising trend in the short … Investors will be thrilled if BCRX’s share price rises to $14, which is the median consensus price. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC.
Deutsche Botschaft Rom Facebook, Everybody Wants Some!!, Ec Red Bull Salzburg Live Ticker, Rb Leipzig Vs Wolfsburg Live Stream, Religionen Des Westens, Oni Maske Kaufen,